Neurogene INC. (NGNE) — SEC Filings

Overview

Neurogene INC. (NGNE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: Neurogene Inc. filed an 8-K on April 20, 2026, reporting changes in its officers and directors, along with compensatory arrangements. The filing also includes a Regulation FD disclosure and financial statements/exhibits.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 46 neutral. The dominant filing sentiment for Neurogene INC. is neutral.

Filing Type Overview

Neurogene INC. (NGNE) has filed 26 8-K, 2 10-K, 5 10-Q, 2 DEF 14A, 8 SC 13G, 1 S-1, 6 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Neurogene Inc. Files 8-K: Officer/Director Changes & Compensation — 8-K · Apr 20, 2026 Risk: low
  Neurogene Inc. filed an 8-K on April 20, 2026, reporting changes in its officers and directors, along with compensatory arrangements. The filing also includes a
• Neurogene's Losses Mount Amid NGN-401 Trial Progress — 10-K · Mar 24, 2026 Risk: high
  Neurogene Inc. (NGNE) reported a net loss of $90.4 million for the fiscal year ended December 31, 2025, an increase from $75.1 million in 2024, bringing its acc
• Neurogene Files 8-K: Q4/FY25 Earnings & Corporate Presentation — 8-K · Mar 24, 2026
  Neurogene Inc. filed an 8-K on March 24, 2026, to announce its results of operations and financial condition, specifically for the fourth quarter and year-end 2
• Neurogene's Losses Widen Amid Increased R&D, Zero Licensing Revenue — 10-Q · Nov 13, 2025 Risk: high
  Neurogene Inc. reported a net loss of $20.95 million for the three months ended September 30, 2025, an increase from $20.22 million for the same period in 2024.
• Neurogene Inc. Files 8-K on Nov 12, 2025 — 8-K · Nov 12, 2025 Risk: medium
  Neurogene Inc. filed an 8-K on November 12, 2025, reporting on events that occurred on the same date. The filing is a current report under the Securities Exchan
• Neurogene Inc. Files 8-K: Regulation FD & Exhibits — 8-K · Nov 6, 2025 Risk: low
  Neurogene Inc. filed an 8-K on November 6, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• Neurogene Inc. Files 8-K with SEC — 8-K · Oct 9, 2025 Risk: low
  Neurogene Inc. filed an 8-K on October 9, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Neoleukin Therap
• Neurogene's Q2 Losses Widen Amid Increased R&D Spend — 10-Q · Aug 11, 2025 Risk: high
  Neurogene Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a gene therapy company. The com
• Neurogene Inc. Files 8-K with Regulatory Updates — 8-K · Jun 30, 2025 Risk: low
  Neurogene Inc. filed an 8-K on June 30, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neol
• Neurogene Inc. Announces Director Changes and Officer Compensation — 8-K · Jun 12, 2025 Risk: medium
  On June 12, 2025, Neurogene Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Jonathan Leff and the appoint
• Neurogene Inc. Files 8-K — 8-K · Jun 9, 2025 Risk: low
  Neurogene Inc. filed an 8-K on June 9, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Neoleukin Therapeu
• Neurogene Inc. Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
  Neurogene Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Neoleukin Therapeutics, Inc., is in the pharmaceutical prepar
• Neurogene Inc. DEF 14A: Executive Pay & Equity Awards Detailed — DEF 14A · Apr 25, 2025 Risk: medium
  Neurogene Inc. filed a DEF 14A with the SEC on April 25, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31,
• Neurogene Inc. Files 8-K: Material Agreement, Other Events — 8-K · Apr 14, 2025 Risk: medium
  On April 14, 2025, Neurogene Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/
• Neurogene Inc. Files 2024 10-K — 10-K · Mar 24, 2025 Risk: medium
  Neurogene Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Neoleukin Therapeuti
• Neurogene Inc. Files 8-K with Financials and Reg FD Disclosure — 8-K · Jan 13, 2025 Risk: low
  Neurogene Inc. filed an 8-K on January 13, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhi
• SC 13G Filing — SC 13G · Dec 11, 2024
• Neurogene Inc. Files S-1 for Public Offering — S-1 · Dec 2, 2024 Risk: medium
  Neurogene Inc. filed an S-1 form on December 2, 2024, to register its securities for a potential public offering. The company, formerly known as Neoleukin Thera
• SC 13G/A Filing — SC 13G/A · Nov 27, 2024
• Neurogene Inc. Files 8-K: Regulation FD Disclosure — 8-K · Nov 21, 2024 Risk: low
  Neurogene Inc. filed an 8-K on November 21, 2024, reporting an event on November 20, 2024. The filing is a Regulation FD Disclosure. The company, formerly known
• Neurogene Inc. Files Q3 2024 10-Q — 10-Q · Nov 18, 2024 Risk: medium
  Neurogene Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., is focused on pharmaceutica
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Neurogene Inc. Files 8-K: Regulation FD & Financials — 8-K · Nov 12, 2024 Risk: low
  Neurogene Inc. filed an 8-K on November 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• SC 13G Filing — SC 13G · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Neurogene Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Nov 4, 2024 Risk: medium
  On November 4, 2024, Neurogene Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securitie
• Neurogene Inc. Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Neurogene Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., reported its financial status an
• Amicus Therapeutics to Acquire Neurogene for $3.9 Billion — 8-K · Aug 7, 2024 Risk: medium
  Neurogene Inc. announced on August 7, 2024, that it has entered into a definitive agreement to be acquired by Amicus Therapeutics, Inc. for approximately $3.9 b
• SC 13G Filing — SC 13G · Jul 8, 2024
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — 8-K · Jun 21, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuk
• Neurogene Inc. Files 8-K Report — 8-K · Jun 18, 2024 Risk: low
  On June 18, 2024, Neurogene Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Neurogene In
• Neurogene Inc. Files 8-K on Security Holder Vote — 8-K · Jun 17, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders on June 14, 2024. The company, formerly known as Neol
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — 8-K · Jun 3, 2024 Risk: low
  Neurogene Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuki
• Neurogene Inc. Files 8-K on Operations and Financials — 8-K · May 10, 2024 Risk: low
  Neurogene Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The c
• Neurogene Inc. Files 8-K with Regulatory Disclosures — 8-K · May 7, 2024 Risk: low
  Neurogene Inc. filed an 8-K on May 7, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin
• Neurogene Inc. Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
  Neurogene Inc. (NGNE) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Neurogene Inc. filed a Definitive Proxy Statement (DEF 14A) on April 26,
• Neurogene Appoints New CMO, Adds Directors — 8-K · Apr 25, 2024 Risk: medium
  Neurogene Inc. announced on April 19, 2024, the appointment of Dr. Steven A. Rosenberg as Chief Medical Officer and the election of Dr. Rosenberg and Dr. David
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — 8-K · Apr 22, 2024 Risk: low
  Neurogene Inc. filed an 8-K on April 22, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neo
• Neurogene Inc. Appoints New Directors, Adjusts Executive Compensation — 8-K · Apr 2, 2024 Risk: medium
  Neurogene Inc. announced on April 1, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Steven M. Altschuler and Dr. Steven A
• Neurogene Inc. Files 8-K on Financials — 8-K · Mar 18, 2024 Risk: low
  Neurogene Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition. The filing indicates the company's principal exec
• Neurogene Inc. Files 8-K for Disclosure and Exhibits — 8-K · Mar 4, 2024 Risk: low
  Neurogene Inc. filed an 8-K on March 4, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleuk
• Neurogene Inc. Reports Executive Changes and Compensation Adjustments — 8-K · Feb 21, 2024 Risk: medium
  Neurogene Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to the departure or election of dir
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Related Companies

AMRX

Frequently Asked Questions